The reiteration of a Neutral rating and maintenance of a $101 price target by Cantor Fitzgerald suggests a stable outlook for Amedisys without immediate significant positive or negative catalysts. This analysis is based on the information provided by the analyst, indicating a belief that the stock is fairly valued at its current level.